The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease
NCT ID: NCT07308418
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
16 participants
INTERVENTIONAL
2025-12-31
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life.
Rationale
Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals.
Participants
Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures.
Study Design and Procedures
Participants attend a single 45-minute session consisting of:
Informed consent and eligibility assessment
Instruction on NUSHU use
Two 2-minute walking tests (with and without vibration), in randomized order
A 15-minute washout between tests
Completion of the System-Usability-Scale (SUS) questionnaire
Continuous monitoring and documentation of safety events and perceived stability
The assessor is blinded regarding the stimulation condition to reduce bias.
Outcomes
Primary outcome:
Difference in self-selected gait speed between vibration vs. no-vibration conditions.
Secondary outcomes:
* Cadence
* Stride length
* Usability (SUS-DE)
* Safety observations and subjective stability ratings
Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation.
Ethics \& Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD.
Purpose:
* Overall, the study aims to understand:
* The short-term effect of vibrotactile stimulation on gait
* The feasibility, usability, and safety of NUSHU in a PD population
* Whether larger, controlled trials are justified
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vibrotactile feedback while walking
Vibrotactile feedback during walking
NUSHU smart shoes give real time gait feedback during walking.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vibrotactile feedback during walking
NUSHU smart shoes give real time gait feedback during walking.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable medication for at least four weeks (no change in dopaminergic therapy).
* The ability to walk at least 200 metres without stopping.
* Minimum age: 18 years
* Sufficient knowledge of German to understand the study information and complete the questionnaires.
* Written informed consent form
Exclusion Criteria
* Sensory disturbances in the feet (e.g. polyneuropathy).
* Other neurological, orthopaedic or internal medical conditions that significantly affect walking
* Cognitive impairments that interfere with understanding the study information or following instructions
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Magnes AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-01560
Identifier Type: -
Identifier Source: org_study_id